Switching from Aflibercept to Ranibizumab May be Beneficial in Patients with Refractory nAMD

Posted on

Patients with neovascular age-related macular degeneration (nAMD) refractory to aflibercept may benefit from switching to ranibizumab, according to a study published in Graefe’s Archive for Clinical and Experimental Ophthalmology.

In a retrospective chart review, 26 patients (32 eyes) with refractory nAMD who switched from monthly intravitreal aflibercept treatment (≥6 months) to ranibizumab, were included.

From baseline (6 months prior to switching) to the time of switching, central retinal thickness increased, before decreasing during the 3 months following the switch. A significant change in visual acuity was not found.

Read the full study here.



Marquis LM, Mantel I. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration [published online ahead of print, 2020 May 12]. Graefes Arch Clin Exp Ophthalmol. 2020;10.1007/s00417-020-04730-8. doi:10.1007/s00417-020-04730-8


Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021